Zegerid generic
Pro Research Analysisby 
Searched over 200M research papers for "zegerid generic"
Zegerid Generic: An Overview of Immediate-Release Omeprazole
Introduction to Zegerid and Its Unique Formulation
Zegerid is a unique formulation of the proton-pump inhibitor (PPI) omeprazole, combined with sodium bicarbonate, designed for immediate release. Unlike other oral PPIs that are delayed-release and enteric-coated to prevent degradation by gastric acid, Zegerid's formulation allows for rapid absorption and action. Each dose of Zegerid contains a significant amount of sodium bicarbonate (1680 mg per 20- or 40-mg packet), which protects omeprazole from gastric acid degradation and facilitates its immediate release1.
Clinical Applications and FDA Approval
Zegerid has been approved by the FDA for several indications, including the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, duodenal ulcers, and gastric ulcers. Notably, it is the only PPI approved for reducing the risk of upper gastrointestinal bleeding in critically ill patients. This makes it particularly useful for patients who are unable to swallow and require medication administration via nasogastric (NG) tubes1 3.
Comparative Efficacy: Zegerid vs. Losec
A Phase III, multicenter, double-blind, randomized study compared the efficacy of Zegerid with Losec (standard enteric-coated omeprazole) for rapid relief of heartburn in GERD patients. The study found no significant difference in the median time to sustained response between the two treatments. Both Zegerid and Losec provided similar times to sustained partial and total relief of heartburn. However, a notable finding was that significantly more patients treated with Zegerid achieved sustained total relief within the first 30 minutes post-dose, highlighting its rapid onset of action2.
Advantages of Immediate-Release Formulation
The immediate-release formulation of Zegerid offers several advantages over traditional delayed-release PPIs. It provides a rapid and sustained elevation of gastric pH, which is particularly beneficial for nighttime control of gastric acidity. This makes Zegerid a suitable option for patients who require flexible dosing schedules and quick relief from symptoms3.
Cost Considerations
While Zegerid offers several clinical benefits, it is important to consider the cost implications. A 14-day treatment with Zegerid costs approximately $70, compared to less than $10 for 14 tablets of over-the-counter Prilosec (another form of omeprazole). This significant cost difference may influence treatment decisions, especially for long-term management of gastric acid-related disorders1.
Conclusion
Zegerid, as an immediate-release formulation of omeprazole, provides rapid and effective relief for various gastric acid-related conditions. Its unique combination with sodium bicarbonate allows for immediate action, making it a valuable option for patients needing quick symptom relief and those with specific medical needs, such as critically ill patients. However, the higher cost compared to other PPIs may be a consideration for some patients. Overall, Zegerid represents a significant advancement in the treatment of gastric acid-related disorders, offering both clinical efficacy and flexibility in dosing.
Sources and full results
Most relevant research papers on this topic
Zegerid--immediate-release omeprazole.
Zegerid is an immediate-release omeprazole formulation that reduces upper GI bleeding risk in critically ill patients and may be useful for patients with nasogastric tubes.
Challenges of Correlating pH Change with Relief of Clinical Symptoms in Gastro Esophageal Reflux Disease: A Phase III, Randomized Study of Zegerid versus Losec
Zegerid and Losec are equally effective for rapid heartburn relief in patients with gastro-esophageal reflux disease, but the rapid onset of action of Losec may be unexpected due to study design factors.
RCT
Rigorous JournalReview of immediate-release omeprazole for the treatment of gastric acid-related disorders
Immediate-release omeprazole provides better nighttime control of gastric acidity than conventional morning dosing, offering flexible dosing and nocturnal gastric acid control.
Divergence and convergence of commercial and scientific priorities in drug development: The case of Zelmid, the first SSRI antidepressant.
Commercial and scientific priorities converged and diverged during the development of Zelmid, the first SSRI antidepressant, with commercial considerations often overriding scientific recommendations.
Characterization of Severity in Zellweger Spectrum Disorder by Clinical Findings: A Scoping Review, Meta-Analysis and Medical Chart Review
Clinical findings and fatty acid levels can predict severity in Zellweger spectrum disorder, aiding in understanding individual prognosis and treatment effectiveness.
Meta-AnalysisIntegrating Network Pharmacology and RT-qPCR Analysis to Investigate the Mechanisms Underlying ZeXie Decoction-Mediated Treatment of Non-alcoholic Fatty Liver Disease
ZeXie Decoction effectively treats non-alcoholic fatty liver disease by targeting HMGCR, SREBP-2, MAPK1, and NF-Bp65 pathways.
Non-RCT
Animal StudyThe use of zein in the controlled release of poorly water-soluble drugs.
Zein shows potential in controlled drug delivery for poorly water-soluble drugs, with potential applications in pharmaceutical and biomedical sciences.
Zein in controlled drug delivery and tissue engineering.
Zein, a plant protein from corn, offers potential for controlled and targeted drug delivery and tissue engineering due to its biodegradable, biocompatible, and safe properties.
Literature Review
Highly CitedApplications of zeolites in biotechnology and medicine - a review.
Zeolites show promise in biotechnology and medicine for environmental protection, detoxication, improved nutrition, biosensors, controlled drug delivery, tissue engineering, and cancer therapy.
Literature ReviewHighly Cited